The CYP2R1 gene encodes vitamin D 25-hydroxylase¹¹ vitamin D 25-hydroxylase
A microsomal cytochrome P450 enzyme expressed primarily in the liver that performs the first obligatory hydroxylation step in vitamin D activation, converting cholecalciferol (D3) or ergocalciferol (D2) into 25-hydroxyvitamin D (25(OH)D), the major circulating form measured in blood tests, the liver enzyme responsible for the first and rate-limiting step in converting dietary or sun-derived vitamin D into the form measured in your bloodstream. Without functional CYP2R1, vitamin D cannot be converted into its bioactive metabolite, regardless of how much sun exposure or supplementation you receive.

rs7936142 is an intronic variant within the CYP2R1 gene on chromosome 11. It was first deployed as a haplotype-tagging marker in linkage studies of CYP2R1 mutations causing vitamin D-deficiency rickets and is now recognized as part of the broader CYP2R1 haplotype block associated with inter-individual variation in circulating 25(OH)D concentrations. The T allele is the minor risk allele, with a global frequency of approximately 9–11%.

The Mechanism

rs7936142 sits in an intronic region of CYP2R1 and does not itself alter the protein sequence. Its association with vitamin D status operates through linkage disequilibrium²² linkage disequilibrium
When two variants on the same chromosome are inherited together more often than chance predicts, so that one variant can serve as a proxy marker for another nearby functional variant with functional variants in the CYP2R1 regulatory or coding regions that reduce enzyme expression or activity. The CYP2R1 protein hydroxylates vitamin D at carbon-25, producing 25-hydroxyvitamin D³³ 25-hydroxyvitamin D
Also written 25(OH)D or calcidiol; this is the storage and transport form measured in clinical vitamin D blood tests, and is the substrate for the kidney enzyme CYP27B1 which makes the active hormone calcitriol (1,25(OH)₂D) — the main circulating form that is subsequently converted to the active hormone calcitriol in the kidneys.

When CYP2R1 expression or activity is reduced by haplotype variants tagged by rs7936142, the liver converts a smaller proportion of incoming vitamin D to 25(OH)D. This creates a state where serum 25(OH)D falls lower than expected for a given vitamin D intake or sunlight exposure — and where the biological ceiling for supplementation response is genetically constrained.

The Evidence

The foundational work establishing CYP2R1's primacy came from Cheng et al. 2004⁴⁴ Cheng et al. 2004
Cheng JB et al. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. PNAS, 2004, who identified a patient with a homozygous L99P mutation in CYP2R1 who had profoundly low 25(OH)D despite normal sun exposure — providing the first genetic proof that CYP2R1 is the principal hepatic 25-hydroxylase in humans.

The clinical relevance of rs7936142 as a haplotype marker was established by Thacher et al. 2015⁵⁵ Thacher et al. 2015
Thacher TD et al. CYP2R1 mutations impair generation of 25-hydroxyvitamin D and cause an atypical form of vitamin D deficiency. J Clin Endocrinol Metab, 2015, who used rs7936142 as one of six linkage markers to map CYP2R1 mutations in Nigerian families with hereditary rickets. Heterozygous carriers of pathogenic CYP2R1 mutations showed markedly reduced 25(OH)D responses to supplementation, confirming semidominant inheritance — a pattern consistent with the intermediate effects seen in common variant heterozygotes.

At the population level, the CYP2R1 locus (tagged by rs7936142 and its haplotype partners rs10741657 and rs10766197) is one of the most replicated GWAS hits for circulating 25(OH)D. A meta-analysis of 52,417 participants⁶⁶ meta-analysis of 52,417 participants
Duan L et al. Effects of CYP2R1 gene variants on vitamin D levels and status: a systematic review and meta-analysis. Gene, 2018 found CYP2R1 risk allele homozygotes had OR 1.42 for vitamin D deficiency (95% CI 1.11–1.83, P = 0.006).

Critically, CYP2R1 variants modulate not just baseline 25(OH)D but also the response to supplementation. An RCT in 616 adolescent girls⁷⁷ RCT in 616 adolescent girls
Khayyatzadeh SS et al. A variant in CYP2R1 predicts circulating vitamin D levels after supplementation with high-dose vitamin D in healthy adolescent girls. J Cell Physiol, 2019 found that rs10741657 AA genotype carriers achieved 539% increases in 25(OH)D after high-dose supplementation versus only 363% in GG carriers — a 50% larger response. This genotype × dose interaction means carriers of the CYP2R1 risk haplotype (including rs7936142 T allele) need higher vitamin D3 doses to reach the same serum 25(OH)D target.

In the MrOS Sweden cohort of 2,870 elderly Swedish men, rs7936142 was successfully genotyped as part of an eight-SNP CYP2R1 haplotype panel. Six of the eight SNPs, including those tagging the haplotype block containing rs7936142, showed 4.6–18.5% differences in mean 25(OH)D values between genotype groups, with the pattern consistent across all markers in the block.

Practical Actions

Carriers of the T allele at rs7936142 — particularly those homozygous for T — tend to run lower in 25(OH)D for a given intake and respond more variably to supplementation. The actionable implication is that standard vitamin D3 doses (600–2,000 IU/day) may be insufficient to maintain 25(OH)D above 30 ng/mL (75 nmol/L), and periodic serum 25(OH)D monitoring is valuable to guide dosing. Using vitamin D3 (cholecalciferol) rather than D2 (ergocalciferol) is advisable since CYP2R1 hydroxylates D3 more efficiently. Cofactors that support CYP2R1 function — particularly magnesium, which is required by all cytochrome P450 enzymes — should be adequate in the diet or supplemented.

Interactions

rs7936142 is a haplotype marker within the CYP2R1 locus and is in linkage disequilibrium with the more extensively studied rs10741657 and rs10766197 variants in the same gene. Individuals carrying risk alleles at multiple CYP2R1 haplotype markers have cumulative reductions in 25(OH)D.

Beyond the CYP2R1 locus, the vitamin D pathway involves four additional genetic bottlenecks: DHCR7/NADSYN1 (skin pre-vitamin D synthesis), GC (transport via vitamin D binding protein, rs4588 and rs7041), CYP27B1 (renal activation), and VDR (receptor sensitivity, rs2228570). The largest GWAS data show that individuals carrying risk alleles across CYP2R1, GC, and DHCR7 can have 2.47-fold increased odds of vitamin D insufficiency compared to those carrying no risk alleles. If you carry risk alleles in multiple pathway genes, the combined effect on 25(OH)D status substantially exceeds any single variant's contribution.

Magnesium is a cofactor for CYP2R1 and other vitamin D pathway enzymes. Magnesium insufficiency (common in modern diets) can impair 25-hydroxylation independent of genetic variation, compounding the effect of CYP2R1 haplotype risk.

The Thr105Ile ¹¹ Threonine to isoleucine at position 105 variant (rs11558538) is a well-characterized missense mutation in the HNMT gene that replaces threonine with isoleucine at position 105. Unlike the 3'UTR variant that affects how much enzyme is made, this variant changes the enzyme's structural stability and catalytic efficiency.

The Mechanism

Position 105 lies near the active site of HNMT where SAM and histamine bind. The isoleucine substitution (T allele) destabilizes the protein, leading to faster degradation and lower steady-state enzyme levels in cells. Studies using recombinant HNMT ²² Recombinant protein is produced in laboratory cells to study enzyme properties in isolation from other cellular factors have shown that the Ile105 variant has reduced thermal stability and lower catalytic activity compared to the wild-type Thr105 enzyme. The threonine residue creates a more accessible conformation of substrate binding residues than the isoleucine variant, resulting in higher enzymatic activity.

The Evidence

Preuss et al. (1998)³³ Preuss et al. (1998)
Preuss CV et al. Human Histamine N-Methyltransferase Pharmacogenetics: Common Genetic Polymorphisms That Alter Activity. Mol Pharmacol, 1998 demonstrated that individuals with the TT genotype had significantly lower HNMT enzyme activity in red blood cells. Subsequent studies confirmed that this variant is associated with increased susceptibility to allergic diseases, asthma, and histamine-related symptoms, particularly in European populations. The variant is relatively uncommon in homozygous form (about 2% of Europeans), but heterozygous carriers (about 18%) may experience subtle effects, particularly when combined with other histamine pathway variants. Interestingly, meta-analyses⁴⁴ meta-analyses
Thr105Ile and Parkinson disease meta-analysis have suggested that the Ile105 variant may be associated with reduced risk of Parkinson disease, possibly through altered brain histamine levels.

Brain Histamine

HNMT is the only enzyme that degrades histamine in the brain, where histamine acts as a neurotransmitter ⁵⁵ Brain histamine is released by tuberomammillary neurons in the hypothalamus and helps regulate the sleep-wake cycle involved in wakefulness, appetite, and cognition. Reduced HNMT activity can alter brain histamine signaling, which may partly explain why some individuals with HNMT variants report sleep disturbances, anxiety, or cognitive effects in response to histamine triggers.

Practical Considerations

If you carry the T allele, supporting your methylation pathway (which supplies SAM for HNMT) becomes even more important, since your enzyme is already working at reduced capacity. Combined with DAO variants, this can create a significant histamine clearance deficit that benefits from both dietary management and methylation support.

Your pancreatic beta cells have a sophisticated system for sensing blood glucose and responding with precisely calibrated insulin release. ADCY5 (adenylate cyclase 5) sits at a critical junction in this signaling chain: it converts a glucose-triggered metabolic signal into cAMP¹¹ cAMP
cyclic AMP — a second messenger molecule that amplifies signals inside cells, in this case activating protein kinase A and Epac proteins to drive insulin granule fusion and secretion, which then drives insulin granule fusion with the cell membrane and release into the bloodstream. The rs11708067 variant near this gene affects how much ADCY5 your islet cells produce — and when that production is reduced, the glucose-to-insulin signal becomes muffled.

The Mechanism

rs11708067 sits in intron 3 of the ADCY5 gene, within what turns out to be a key regulatory enhancer active specifically in pancreatic islets. The A risk allele disrupts this enhancer. Functional studies by Roman and colleagues²² Roman and colleagues
Roman TS et al. A Type 2 Diabetes-Associated Functional Regulatory Variant in a Pancreatic Islet Enhancer at the ADCY5 Locus. Diabetes, 2017 showed that the A allele carries fewer active chromatin marks (H3K27ac) in human islets, has lower transcriptional activity in reporter assays, and increased nuclear protein binding — all signs of a disrupted enhancer. When the equivalent enhancer region was deleted in a beta-cell line, ADCY5 expression fell by 64% and insulin secretion dropped by 39%.

The consequence is selective: Hodson and colleagues³³ Hodson and colleagues
Hodson DJ et al. ADCY5 Couples Glucose to Insulin Secretion in Human Islets. Diabetes, 2014 demonstrated that ADCY5 is specifically required for translating elevated glucose concentrations into cAMP production. When ADCY5 is silenced, glucose-stimulated cAMP generation falls nearly threefold and insulin secretion is substantially impaired — but GLP-1-stimulated secretion remains intact because GLP-1 activates other adenylyl cyclase isoforms. Risk allele carriers show approximately twofold lower ADCY5 mRNA expression in islets, particularly in younger male AA carriers. A secondary defect has also been documented: Wagner and colleagues⁴⁴ Wagner and colleagues
Wagner R et al. Glucose-raising genetic variants in MADD and ADCY5 impair conversion of proinsulin to insulin. PLoS One, 2011 found that A allele carriers show impaired proinsulin-to-insulin conversion, meaning beta cells produce proportionally more of the inactive precursor form.

The Evidence

The original discovery came from a landmark meta-analysis⁵⁵ landmark meta-analysis
Dupuis J et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet, 2010 of 21 genome-wide association studies in up to 46,186 non-diabetic participants with follow-up in an additional 76,558 individuals. rs11708067 emerged as one of nine newly discovered fasting glucose loci, with each A allele associated with a +0.027 mmol/L (0.49 mg/dL) increase in fasting glucose (p=7.1×10⁻²²) and OR 1.12 for type 2 diabetes (p=9.9×10⁻²¹). Crucially, the variant was associated with reduced HOMA-B (beta-cell function) but not HOMA-IR (insulin resistance), confirming the effect is specifically on insulin secretion capacity, not insulin sensitivity.

Replication across ethnicities strengthens the evidence. A South Asian study⁶⁶ South Asian study
Rees SD et al. Effects of 16 genetic variants on fasting glucose and type 2 diabetes in South Asians: ADCY5 and GLIS3 variants may predispose to type 2 diabetes. PLoS One, 2011 in 1,678 cases and 1,584 controls confirmed OR 1.23 (95% CI 1.09–1.39, p=9.1×10⁻⁴). Pathway studies in GWAS of early childhood glucose levels also found ADCY5 rs11708067 among the variants cumulatively raising plasma glucose by 0.053 mmol/L per risk allele from birth onward.

The developmental origin of this risk was confirmed by Aguilera-Venegas and colleagues⁷⁷ Aguilera-Venegas and colleagues
Aguilera-Venegas A et al. Association of diabetes-related variants in ADCY5 and CDKAL1 with neonatal insulin, C-peptide, and birth weight. Endocrine, 2021 who showed that healthy newborns carrying the A allele had lower cord blood insulin and C-peptide concentrations, independent of maternal glycemia — demonstrating that reduced beta-cell insulin secretion capacity is present from the first moments of life.

Practical Actions

The ADCY5 glucose-signaling deficit operates specifically on the glucose→cAMP pathway. This creates a specific therapeutic relevance: because GLP-1 stimulated secretion is ADCY5-independent, GLP-1 receptor agonists (semaglutide, liraglutide) and DPP-4 inhibitors work through a preserved pathway in risk allele carriers. For AA homozygotes with elevated fasting glucose or impaired glucose tolerance, these incretin-based approaches may be particularly rational choices to discuss with a physician.

Dietary strategies that blunt the glucose spike — lower glycemic load meals, slower carbohydrate absorption — reduce the demand on the already-reduced ADCY5-mediated secretion capacity. Continuous glucose monitoring can reveal whether postprandial responses are adequate despite the secretion deficit. Given the proinsulin conversion defect, fasting proinsulin:insulin ratio can serve as a sensitive early marker of beta-cell stress in high-risk individuals.

Interactions

ADCY5 rs11708067 sits within a broader beta-cell function locus. The neighboring SNP rs2877716 (C allele) tags the same ADCY5 risk haplotype and is often genotyped in parallel studies. Co-carriage of rs11708067 risk alleles with SLC30A8 rs13266634 (zinc transporter 8) compounds beta-cell secretory dysfunction through independent mechanisms — ZnT8 affects insulin granule maturation while ADCY5 affects the upstream glucose-to-cAMP signal. Individuals carrying risk alleles at both loci show a convergent impairment in glucose-stimulated insulin release. TCF7L2 rs7903146 risk alleles further compound risk through a third mechanism involving incretin signaling and beta-cell development; population studies of early childhood glucose levels found ADCY5 and TCF7L2 variants among the most consistently replicated contributors to cumulative fasting glucose elevation.

The brain's immune cells — microglia — are its primary defence against accumulating amyloid-beta plaques, the toxic protein deposits that define Alzheimer's disease. To stay activated and effective, microglia rely on a molecular on-switch: the interleukin-1 signalling complex¹¹ interleukin-1 signalling complex
IL-1 cytokine signalling is critical for microglial reactivity, phagocytosis, and amyloid clearance, which includes the receptor accessory protein encoded by IL1RAP. The rs12053868 variant sits in an intron of this gene and — through regulatory changes in expression — subtly dampens the IL-1 signal that keeps microglia primed to clear amyloid. The result is measurable: a small but steady increase in the pace at which amyloid accumulates in the aging brain.

The Mechanism

IL1RAP encodes interleukin-1 receptor accessory protein²² interleukin-1 receptor accessory protein
IL1RAP forms an obligate co-receptor with IL1R1; neither unit can transduce IL-1β or IL-1α signals alone, an essential co-receptor subunit in the IL-1 signalling complex. When IL-1β binds, the IL1R1/IL1RAP heterodimer recruits MyD88 and triggers NF-κB, driving microglial reactivity, cytokine secretion, and phagocytic activity. rs12053868 lies in intron 3 at genomic position chr3:190,582,215 (GRCh38), on the plus strand. As an intronic regulatory variant it does not change the amino acid sequence of IL1RAP; instead it appears to act as an expression quantitative trait locus³³ expression quantitative trait locus
eQTL variants alter how much of a gene's protein is produced, not its structure that mildly reduces IL1RAP transcription in microglial and neuronal cells. Lower IL1RAP levels attenuate the IL-1 signalling cascade, reducing microglial responsiveness to early amyloid deposits — allowing plaques to accumulate before the immune response clears them. Separate mouse knockout data confirms that global loss of IL-1RAcP (the IL1RAP protein) reduces pathological tau phosphorylation⁴⁴ reduces pathological tau phosphorylation
pS202 and pT231 tau epitopes are reduced in LPS-challenged Il1rap knockout mice in inflammatory contexts, underscoring the pathway's centrality to both amyloid and tau pathology.

The Evidence

The primary evidence comes from a 2015 genome-wide association study⁵⁵ 2015 genome-wide association study
Ramanan et al., ADNI cohort, longitudinal 18F-florbetapir PET imaging over 2 years published in Brain that measured longitudinal amyloid accumulation — not just amyloid burden at a single point in time, but the rate at which amyloid built up year by year. In the ADNI cohort, each G allele copy was associated with a 0.8% per-year increase in cortical amyloid standardised uptake value ratio (SUVR), reaching genome-wide significance at p = 1.38×10⁻⁹. Critically, the association held independently of APOE ε4 — the strongest known Alzheimer's genetic risk factor — establishing IL1RAP as an orthogonal risk pathway. G allele carriers also showed greater temporal-cortex atrophy on MRI, accelerated progression from mild cognitive impairment to Alzheimer's disease, and lower cortical ¹¹C-PBR28 PET signal (a marker of microglial activation), directly connecting reduced IL1RAP activity to impaired microglial surveillance.

A 2019 Swedish study⁶⁶ 2019 Swedish study
Zettergren et al., N=3,446 cases/controls, N=1,400 for CSF biomarker analyses extended these findings to CSF biomarkers. While IL1RAP variants did not significantly alter lifetime Alzheimer's disease risk in this sample, they were significantly associated with elevated CSF total-tau and phospho-tau concentrations — biomarkers of neuronal injury and tangle formation that predict disease progression. The researchers concluded that IL1RAP genetic variation influences disease intensity (how aggressively neurodegeneration proceeds) rather than merely disease susceptibility, consistent with the amyloid accumulation rate finding.

The variant's minor-allele frequency differs substantially by ancestry: ~11% in Europeans, ~14% in East Asians, but only ~2% in Africans of African descent. This pattern means the G allele's impact on population-level Alzheimer's risk is most pronounced in East Asian and European communities.

Practical Actions

No drug or supplement has been proven to specifically reverse impaired IL1RAP signalling in humans. However, because the risk mechanism runs through microglial activation and neuroinflammation⁷⁷ microglial activation and neuroinflammation
Microglia clear amyloid by phagocytosis; dampened IL-1 signalling slows this process, strategies that support microglial function and reduce chronic neuroinflammation are the most plausible targets. Long-chain omega-3 fatty acids (EPA/DHA) modulate microglial phenotype toward a more phagocytic, amyloid-clearing state. Maintaining tight control of systemic inflammatory markers (hsCRP, IL-6) reduces the chronic inflammatory background that dysregulates the very IL-1 pathway this variant affects. Monitoring cognitive biomarkers (CSF tau/amyloid, or plasma p-tau181 where available) earlier than usual can establish baseline values and flag accelerated change.

Interactions

The effect of rs12053868 is independent of APOE ε4 (rs429358 / rs7412), meaning carriers of both face compounded risk through separate biological pathways: APOE ε4 reduces direct amyloid clearance efficiency, while rs12053868-G reduces the microglial surveillance that removes plaques at the source. The CLU rs11136000 (clusterin) variant acts in the same amyloid clearance biology; individuals carrying risk alleles in both genes may have meaningfully elevated cumulative risk. IL1RAP co-variation with rs9877502 — a separate IL1RAP locus associated with CSF tau — has not yet been formally modelled but represents a plausible intra-gene interaction worth monitoring as longitudinal cohort data mature.

About 19 kilobases downstream of IL2RA¹¹ IL2RA
the gene encoding CD25, the alpha chain of the high-affinity interleukin-2 receptor; CD25 is the defining surface marker of regulatory T cells (Tregs), rs12251307 sits in a region of open chromatin that functions as a long-range regulatory element for the locus. IL-2 signaling through CD25 is the central survival and activation signal for regulatory T cells²² regulatory T cells
Tregs are CD4+ immune cells that suppress excessive immune responses and maintain self-tolerance; CD25 gives Tregs preferential access to IL-2 at physiologically low concentrations. Variants across the IL2RA locus — including rs12251307 — collectively tune how much CD25 gets expressed on Treg surfaces, how sensitive those Tregs are to IL-2, and consequently how well the immune system is held in check. The T allele at this downstream position tags a configuration of the locus associated with mildly impaired immune regulation across multiple atopic and autoimmune phenotypes.

The Mechanism

rs12251307 is located on the plus strand of chromosome 10 at position 6,081,532 (GRCh38), classified as an intergenic variant with C as the GRCh38 reference allele and T as the alternate. The region around IL2RA contains multiple independent regulatory variants that together influence sIL-2RA shedding³³ sIL-2RA shedding
the alpha chain of the IL-2 receptor can be cleaved and released from the cell surface as soluble IL-2RA, which competes with membrane-bound receptors for available IL-2, thereby reducing the effective IL-2 signal reaching Tregs, intron-1 enhancer activity, and promoter accessibility. The T allele at rs12251307 acts as a tag for a broader haplotype across this ~20 kb region. Because IL2RA is on the minus strand, gene regulatory elements can extend well beyond the transcribed sequence into the 3' flank, and enhancer-promoter loops at this distance are well documented in immune loci. Mechanistically, T-allele haplotypes at this locus are associated with lower Treg STAT5 phosphorylation⁴⁴ Treg STAT5 phosphorylation
STAT5 is the intracellular signaling molecule activated when IL-2 binds to CD25-containing high-affinity receptor complexes; less pSTAT5 means weaker Treg activation even when IL-2 is present and reduced Treg suppressive capacity downstream of IL-2 stimulation.

The Evidence

The strongest signal comes from the 2023 Nature Communications atopic dermatitis GWAS meta-analysis. Budu-Aggrey et al. analyzed hundreds of thousands of individuals across European and multi-ancestry cohorts⁵⁵ Budu-Aggrey et al. analyzed hundreds of thousands of individuals across European and multi-ancestry cohorts, identifying rs12251307-T as a genome-wide significant risk allele for atopic dermatitis (OR 1.10, 95% CI 1.09–1.11; p = 5×10⁻¹⁰⁷). The paper explicitly highlighted the IL2RA locus as evidence that atopic dermatitis involves systemic immune dysregulation — not just skin-barrier defects — placing it alongside classic HLA and cytokine loci. The T allele risk frequency in the atopic dermatitis cohort was ~12%.

Earlier evidence established this locus in type 1 diabetes: the Type 1 Diabetes Genetics Consortium meta-analysis (Barrett et al. 2009)⁶⁶ Type 1 Diabetes Genetics Consortium meta-analysis (Barrett et al. 2009) identified the same 10p15 region at genome-wide significance (p = 1×10⁻¹³), consistent with the IL2RA locus being a shared hub for autoimmune susceptibility. A 2023 cross-trait GWAS also found rs12251307 among loci shared between rheumatoid arthritis and type 1 diabetes (Wen & Yu 2023)⁷⁷ (Wen & Yu 2023). The variant also reaches genome-wide significance for asthma susceptibility (OR ~1.09, p = 2×10⁻⁹), extending the phenotypic spectrum to atopic disease more broadly. The functional biology underlying all these associations is coherent: Treg dysfunction resulting from impaired CD25 expression or IL-2 signaling permits both autoimmune attack (T1D, RA) and dysregulated type 2 immune responses (atopic dermatitis, asthma) depending on the downstream context.

Practical Actions

The T allele confers a small per-allele risk increase (OR ~1.10 per T copy). In absolute terms, the lifetime risk increase is modest but meaningful in context of a personal or family history of atopic or autoimmune conditions. Carriers cannot directly manipulate CD25 expression, but the downstream biology — Treg function and IL-2 signaling — is modulated by vitamin D status and IL-2 availability. The most clinically actionable implication for T allele carriers is awareness of early-onset warning signs across atopic and autoimmune phenotypes and timely engagement with a dermatologist or immunologist when symptoms arise.

Interactions

rs12251307 is in the same genomic locus as several other IL2RA variants already catalogued: rs2104286⁸⁸ rs2104286 (intron 1, soluble IL-2RA shedding), rs12722489⁹⁹ rs12722489 (intron 1, estrogen-responsive enhancer), rs41295061¹⁰¹⁰ rs41295061 (regulatory, T1D locus), and rs2256774¹¹¹¹ rs2256774 (intronic). These variants are in partial linkage disequilibrium; rs12251307 represents an additional, partially independent signal at the 3' end of the locus. Compound heterozygosity across multiple IL2RA locus variants may further impair Treg function, though the specific interaction effects have not been quantified for this downstream position. The locus also interacts biologically with IL-2 pathway genes including IL2RB¹²¹² IL2RB and IL2¹³¹³ IL2; variants in these genes that reduce IL-2 production or beta-chain signaling would compound the signaling deficit created by impaired CD25 expression.

PPARG (peroxisome proliferator-activated receptor gamma) is the master transcriptional regulator of adipogenesis¹¹ Adipogenesis: the process by which precursor cells differentiate into mature fat-storing adipocytes. PPARG drives expression of hundreds of genes controlling lipid storage, fatty acid uptake, and insulin signaling in fat tissue. and a central hub for insulin sensitivity throughout the body. The PPARG gene spans more than 100 kilobases on chromosome 3p25 and contains at least 14 transcript variants — a structural complexity that creates multiple potential sites where common intronic variants can alter splicing, enhancer activity, or long-range gene regulation.

rs12490265 is a common intronic variant (G>A) at GRCh38 chr3:12,343,043, positioned near the 5′ end of the PPARG gene body. It is not a coding change — no amino acid is altered. Its significance lies in its role as part of the PPARG metabolic haplotype block: a set of physically linked intronic variants that collectively tag distinct patterns of PPARG pathway activity in metabolically active tissues.

The Mechanism

rs12490265 sits within the PPARG gene but upstream of the canonical exonic variants (Pro12Ala at rs1801282, His477His at rs3856806). Its location near the 5′ region of the gene places it within or near intronic regulatory elements that may influence promoter usage, alternative splicing efficiency, or interaction with adipose tissue– specific enhancers. The precise molecular mechanism has not been functionally characterized in cell or animal models — but intronic SNPs in this region of PPARG are known to alter adipogenesis-related gene network activity²² adipogenesis-related gene network activity
Intronic variants can act as splicing regulatory elements, alter local chromatin state, or disrupt binding sites for transcription factors — all without changing the protein sequence. in population studies.

The variant is in linkage disequilibrium with rs1175543 and rs1797912 — other intronic PPARG variants — forming a haplotype block that spans a large portion of the PPARG 5′ region. When these variants travel together in the protective configuration (AGCC haplotype: rs3856806T + rs12490265A + rs1797912C + rs1175543G), metabolic syndrome risk is reduced compared to the common GGAG configuration.

The Evidence

A case-control study of 489 Kazakh subjects³³ case-control study of 489 Kazakh subjects
Guo et al. Analysis of the haplotype and linkage disequilibrium of PPARγ gene polymorphisms rs3856806, rs12490265, rs1797912, and rs1175543 among patients with metabolic syndrome in Kazakh of Xinjiang Province. Genet Mol Res, 2014 found that the rs12490265 A allele frequency was significantly lower among metabolic syndrome patients than among controls (31.84% vs 38.52%, P = 0.029), indicating that A allele carriers are under-represented in people with metabolic syndrome. The four-variant AGCC haplotype (incorporating the A allele at rs12490265) was identified as a protective haplotype against metabolic syndrome in this population. The companion haplotype analysis also showed that the A allele tracks closely with the T allele at rs3856806 (His477His), which has independently replicated associations with reduced T2D risk and improved LDL-C and HDL-C across tens of thousands of individuals in meta-analyses.

A large prospective cohort⁴⁴ prospective cohort
Gallicchio et al. Genetic polymorphisms of PPAR and risk of cardiovascular morbidity and mortality in CLUE-II. PPAR Res, 2008 tracking 9,364 Caucasians found that the broader PPARG intronic haplotype block (encompassing rs1175543 and rs709158, which share strong LD with rs12490265) associated with baseline total cholesterol levels. No association with cardiovascular mortality was detected, suggesting the variant's influence is metabolic rather than directly vascular.

A longitudinal study⁵⁵ longitudinal study
Black et al. Variation in PPARG is associated with longitudinal change in insulin resistance in Mexican Americans at risk for T2D. J Clin Endocrinol Metab, 2015 genotyped 18 tag SNPs spanning the PPARG locus in 378 participants over 4.6 years and found that several non-Pro12Ala PPARG variants — independent of adiposity changes — significantly predicted declining insulin sensitivity. This reinforces that the PPARG haplotype block carries independent metabolic information beyond the canonical Pro12Ala variant.

The evidence for rs12490265 as an independent functional variant is emerging: the primary metabolic syndrome association comes from a single study in one ethnic group. Its biological significance is best understood as a marker for the broader PPARG haplotype rather than as a stand-alone functional variant.

Practical Actions

For GG homozygotes (~53% of people globally), the PPARG haplotype at this locus is the common baseline — the A allele's partial metabolic protection is absent. Monitoring fasting glucose, HbA1c, and a full lipid panel provides a direct readout of PPARG pathway function that is especially relevant when other PPARG risk variants (Pro/Pro at rs1801282, CC at rs3856806) are also present.

Interactions

rs12490265 is part of the PPARG intronic haplotype block that also includes rs1175543, rs1797912, and rs709158. Strong linkage disequilibrium ties these variants together across much of the PPARG gene body. The protective AGCC haplotype (rs3856806T + rs12490265A + rs1797912C + rs1175543G) confers a combined metabolic syndrome risk reduction beyond any single variant. The key coding-variant context is rs1801282 (Pro12Ala): carriers of both the GG genotype here (no A-allele protection) and the CC genotype at rs1801282 (Pro/Pro, the T2D-risk haplotype) accumulate the most PPARG- related metabolic risk across this gene.

CYP2C8 is one of the body's principal drug-processing enzymes, responsible for clearing roughly 5% of all commonly prescribed medications. Its substrates span remarkably diverse drug classes: the antidiabetics repaglinide and rosiglitazone, the chemotherapy agent paclitaxel, the antimalarial amodiaquine, and several NSAIDs including ibuprofen. Beyond drug metabolism, CYP2C8 converts arachidonic acid into [epoxyeicosatrienoic acids (EETs) | lipid signaling molecules with vasodilating, anti-inflammatory, and bone-protective properties], making CYP2C8 activity relevant far outside the pharmacy.

rs1341162 sits in intron 5 of CYP2C8 on chromosome 10 (GRCh38 position 95,050,855) and does not directly alter the enzyme's amino acid sequence. Its significance lies in what it tags: a broader intronic haplotype block that cosegregates with altered CYP2C8 expression and activity.

The Mechanism

The T allele at rs1341162 travels together with the T allele at rs1934951¹¹ rs1934951
intron 8 variant; the most strongly MRONJ-associated CYP2C8 SNP and the T allele at rs1934980, forming the "TGT" haplotype first identified by Sarasquete et al., Blood 2008²² Sarasquete et al., Blood 2008
PMID 18594024. This haplotype was present in 45% of bisphosphonate-treated multiple myeloma patients who developed osteonecrosis of the jaw, compared with only 10% of controls — an odds ratio exceeding 7. The complementary "CAC" haplotype (the C allele at all three positions) was the protective common form (83% in controls vs 50% in cases).

The exact molecular mechanism by which intronic variants in this haplotype alter CYP2C8 function remains incompletely characterized. Intronic variants can affect [pre-mRNA splicing | intronic sequences contain regulatory elements that guide the spliceosome], create or destroy branch points, or alter regulatory elements recognized by RNA-binding proteins. Functional studies of related CYP2C8 intronic haplotypes (the "haplotype B" described by Rodríguez-Antona et al., 2007³³ Rodríguez-Antona et al., 2007
PMID 17923851) showed significantly increased paclitaxel 6α-hydroxylation in liver microsomes, suggesting at least some intronic variants in this region do alter expression or splicing.

The Bisphosphonate Connection

The leading hypothesis connecting CYP2C8 to [medication-related osteonecrosis of the jaw (MRONJ) | jaw bone death complicating bisphosphonate treatment in ~5% of cancer patients receiving high-dose IV therapy] is EET-mediated. CYP2C8 produces EETs from arachidonic acid, and EETs have been shown to directly suppress osteoclast formation, inhibit NF-κB and RANKL signaling in bone cells, and reduce inflammatory cytokines (TNF-α, IL-1β) that drive bone resorption (Norwood et al., 2014⁴⁴ Norwood et al., 2014
PMID 25466887). If the TGT haplotype reduces CYP2C8 activity and lowers EET output in jaw bone, it may create a permissive inflammatory environment in which the additional bone-metabolic stress of bisphosphonates — which suppress osteoclast renewal, impair angiogenesis, and trap necrotic fragments — tips into clinical necrosis.

The Evidence

The discovery study by Sarasquete et al. used 500,568 SNPs across 22 multiple myeloma cases with MRONJ and 65 matched controls; rs1341162 reached p = 6.22 × 10⁻⁶ (below the Bonferroni-corrected threshold of p = 1 × 10⁻⁷ for that array). The stronger signal came from rs1934951 (p = 1.07 × 10⁻⁶; OR 12.75), which is in strong LD with rs1341162. A replication study by Such et al. (Haematologica, 2011; PMID 21685474⁵⁵ PMID 21685474) in 79 myeloma patients could not confirm a statistically significant association, illustrating the modest statistical power of these relatively small cohorts. A meta-analysis of rs1934951 (the lead SNP in this block) found pooled OR ~3.2 across available studies, consistent with a real but attenuated effect (PMID 23171856⁶⁶ PMID 23171856).

For the drug-metabolism dimension, intronic CYP2C8 haplotypes shift paclitaxel, repaglinide, and amodiaquine pharmacokinetics in population studies, though the effect size is smaller than for the nonsynonymous CYP2C8*3 allele (rs10509681 + rs11572080). The evidence level for rs1341162 specifically is moderate — the haplotype association is replicated but the mechanistic connection remains incompletely resolved.

Practical Actions

Carriers of the TT genotype (approximately 9% globally, 4% in Europeans) carry the full dose of the risk haplotype. For patients facing bisphosphonate treatment — particularly high-dose intravenous therapy with zoledronic acid or pamidronate for multiple myeloma or bone metastases — knowledge of this variant status provides an early signal to intensify dental surveillance before starting treatment. For oncologists managing paclitaxel-based regimens, CYP2C8 haplotype status may be one factor to consider alongside the more established CYP2C8*3 genotype when calibrating dose-related neuropathy risk.

Interactions

rs1341162 is part of a broader intronic haplotype block with rs1934951 and rs1934980. Its effects compound with the nonsynonymous CYP2C8*3 allele (defined by rs11572080 and rs10509681), which reduces enzyme activity to ~50% of wild-type. Individuals carrying both the TGT intronic haplotype and one or two CYP2C8*3 alleles have the most reduced CYP2C8 capacity and, in theory, the greatest MRONJ and drug-accumulation risk.

The low-density lipoprotein receptor (LDLR)¹¹ low-density lipoprotein receptor (LDLR)
a transmembrane protein on liver and other cells that binds LDL particles and pulls them out of circulation is the central traffic controller of blood cholesterol. Every cell that needs cholesterol expresses LDLR; liver cells express the most, and it is there that the majority of circulating LDL-cholesterol is cleared from the bloodstream. When LDLR is silenced by a pathogenic mutation, LDL accumulates unchecked — the primary cause of familial hypercholesterolemia (FH)²² familial hypercholesterolemia (FH)
an inherited condition characterized by lifelong severely elevated LDL-cholesterol and premature atherosclerotic cardiovascular disease.

This position (c.1222, codon 408) is a multi-allelic hotspot in LDLR. The most severe allele — the T allele profiled here — introduces a premature stop codon at glutamic acid 408 (p.Glu408Ter, also written E408*), truncating the protein and completely abolishing receptor function. Two other alleles exist at the same position: G>C (p.Glu408Gln, missense, uncertain significance per ClinGen expert panel) and G>A (p.Glu408Lys, missense, associated with hypercholesterolemia in case series). All three are absent from large population databases, confirming their ultra-rare pathogenic status.

The Mechanism

The Glu408Ter nonsense mutation introduces a TGA stop codon at position 408 of the 860-amino-acid LDLR protein, midway through the epidermal-growth-factor (EGF) precursor homology domain³³ epidermal-growth-factor (EGF) precursor homology domain
a region required for receptor recycling after LDL delivery; without it, receptors cannot release LDL in the endosome and return to the cell surface. The truncated mRNA is typically degraded by nonsense-mediated decay, meaning the cell produces essentially no functional LDLR protein from this allele.

Tabet et al. 2026 (Science)⁴⁴ Tabet et al. 2026 (Science) experimentally tested nearly all possible LDLR coding variants, generating a comprehensive sequence-function map. Nonsense/stop-gain variants — including all premature stop codons in the receptor's extracellular and transmembrane domains — uniformly produced zero detectable cell-surface LDLR expression and zero LDL uptake, consistent with complete loss of function. This classification as a Class 1 (synthesis-null) or Class 5 (no LDL uptake) variant places it among the most severe LDLR mutation classes.

Heterozygous carriers have one functional LDLR allele and one null allele, reducing receptor density on hepatocytes by approximately 50%. This halved clearance capacity produces the hallmark heterozygous FH phenotype: LDL-cholesterol typically in the range of 190–400 mg/dL (normal: below 100 mg/dL in adults at low cardiovascular risk). Homozygous carriers (two null alleles) have essentially no functional LDLR and LDL-C levels exceeding 500 mg/dL, with xanthomas, corneal arcus, and coronary artery disease appearing in childhood.

The Evidence

Marduel et al. 2010 (Human Mutation)⁵⁵ Marduel et al. 2010 (Human Mutation) surveyed the molecular spectrum of autosomal dominant hypercholesterolemia in 1,358 French probands, identifying 391 distinct LDLR mutation events. Nonsense mutations — the class to which Glu408Ter belongs — accounted for 11.3% of all unique pathogenic events, consistently associated with the most severe LDL-C elevations and the highest cardiovascular disease penetrance.

The ClinVar expert panel classification for the nonsense allele is Pathogenic (VCV001371905), submitted by Labcorp Genetics with functional evidence that the stop-gain creates an absent or disrupted protein product. Loss-of-function LDLR variants are among the most robustly validated pathogenic variant classes in human genetics, with over 1,700 disease-causing LDLR variants catalogued in the ClinVar/ClinGen FH database.

Epidemiologically, heterozygous FH affects approximately 1 in 200–250 individuals globally, making it one of the most common inherited metabolic disorders. Without treatment, heterozygous men with FH face a 50% risk of coronary heart disease by age 50; women by age 60. The GeneReviews FH overview⁶⁶ GeneReviews FH overview documents that untreated adults with FH have a coronary heart disease risk 10- to 20-fold higher than age-matched controls.

Practical Actions

The evidence for statin therapy in FH is unambiguous. High-intensity statins (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) reduce LDL-C by 50–60% and dramatically reduce cardiovascular event rates in FH patients. For carriers who cannot achieve LDL-C targets on statins alone — a common finding given the severity of the receptor defect — combination therapy with ezetimibe (which blocks intestinal cholesterol absorption) and/or PCSK9 inhibitors (evolocumab, alirocumab) can achieve further 50–70% reductions on top of statins. The RNA-targeted therapy inclisiran offers an alternative for those requiring additional LDL-C lowering.

Dietary modification is an important but insufficient standalone intervention in LDLR null carriers. Reducing saturated fat intake to below 7% of total calories and limiting dietary cholesterol decreases LDL-C synthesis burden, but because the fundamental defect is clearance failure rather than overproduction, dietary changes alone rarely bring LDL-C into the target range. Medications are required.

Cascade screening — testing first-degree relatives — is the single most cost-effective cardiovascular prevention intervention for FH families. Each affected parent has a 50% chance of passing this autosomal dominant variant to each child.

Interactions

LDLR null variants have a well-documented interaction with APOE genotype. rs429358⁷⁷ rs429358 (APOE ε4) independently impairs LDL clearance via a separate mechanism — APOE ε4 binds LDL receptors with reduced efficiency compared to APOE ε3. Carrying both an LDLR null allele and APOE ε4 compounds the LDL-clearance defect beyond the sum of either variant alone, and such individuals may have more severely elevated LDL-C and earlier cardiovascular disease onset than predicted from the LDLR variant alone.

The PCSK9 gene (rs11591147, rs562556) encodes a protein that degrades LDLR. Loss-of-function PCSK9 variants that increase LDLR surface density — naturally reducing LDL-C — can partially mitigate the severity of heterozygous FH. Conversely, PCSK9 gain-of-function variants (which further reduce LDLR) would compound the LDLR null allele's effects. These interactions explain why PCSK9 inhibitor drugs are particularly effective in LDLR-deficient patients.

The CLOCK gene (Circadian Locomotor Output Cycles Kaput) sits at the top of the mammalian circadian hierarchy. CLOCK protein¹¹ CLOCK protein
A basic helix-loop-helix transcription factor encoded on chromosome 4 that heterodimerizes with BMAL1 to drive 24-hour gene expression rhythms across virtually every tissue in the body heterodimerizes with BMAL1 and binds E-box elements in the promoters of core clock genes including Per1, Per2, Cry1, and Cry2, generating the transcription-translation feedback loop that keeps cellular time. This same molecular oscillator gates metabolic processes — glucose uptake, lipid synthesis, and hormone secretion all oscillate under circadian control.

The rs1554483 variant (chr4:55,455,650, GRCh38) lies deep within an intron of CLOCK, approximately 100 kb from the better-known 3'UTR variant rs1801260. Although it does not alter any amino acid and its precise molecular mechanism has not been characterized at single-nucleotide resolution, it forms part of a two-variant haplotype with rs4864548 that has been replicated across multiple studies as a risk marker for obesity, non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome — particularly in the context of circadian disruption from shift work.

The Mechanism

rs1554483 is an intron variant²² intron variant
A nucleotide change within a non-coding intron; may affect splicing efficiency, enhancer elements, or gene expression level without altering the protein sequence directly in one of CLOCK's 16 annotated transcript isoforms. Its molecular effect has not been characterized in cell-based assays, but given that CLOCK's intronic regulatory landscape contains numerous enhancer elements and splice-regulatory sequences, plausible mechanisms include altered intronic enhancer activity³³ intronic enhancer activity
Enhancers within introns can loop to interact with the promoter and regulate transcription levels; variants in these regions can modulate expression in a tissue-specific manner or subtle effects on CLOCK mRNA splicing efficiency.

What is better established is the biological consequence: disrupted CLOCK function compromises the timing of metabolic gene expression. Mice with circadian clock disruption — including CLOCK mutant lines — develop obesity, hyperlipidemia, hyperglycemia, and fatty liver on standard chow, demonstrating that the circadian machinery directly controls energy balance. Human intronic CLOCK variants that alter expression levels or isoform balance in metabolically relevant tissues (liver, adipose, hypothalamus) are mechanistically plausible candidates for the metabolic associations observed in the epidemiological data.

The Evidence

Obesity and haplotype risk. Sookoian et al. (2008)⁴⁴ Sookoian et al. (2008)
Sookoian S et al. Genetic variants of Clock transcription factor are associated with individual susceptibility to obesity. Am J Clin Nutr, 2008 genotyped six tag SNPs across CLOCK in 1,106 adults (715 lean, 391 obese/overweight). The rs1554483G — rs4864548A paired haplotype was found in 47% of obese individuals versus 41% of lean controls, corresponding to a 1.8-fold odds for overweight or obesity (P = 0.011). Among the individual SNPs, rs1554483 showed one of the four significant obesity associations.

NAFLD and liver disease. Sookoian et al. (2007)⁵⁵ Sookoian et al. (2007)
Sookoian S et al. Common genetic variations in CLOCK transcription factor are associated with nonalcoholic fatty liver disease. World J Gastroenterol, 2007 studied 136 NAFLD patients and 64 healthy controls (91 patients with liver biopsies). rs1554483 was among the variants showing a significant association with both clinical NAFLD spectrum (P = 0.0399) and fibrosis score (P = 0.027). CLOCK haplotype frequencies differed significantly between NAFLD and healthy groups (P = 0.0097), placing this variant within a haplotypic context linked to fatty liver susceptibility and progression.

Metabolic syndrome in shiftworkers. Sookoian et al. (2010)⁶⁶ Sookoian et al. (2010)
Sookoian S et al. Gene-gene interaction between serotonin transporter (SLC6A4) and CLOCK modulates the risk of metabolic syndrome in rotating shiftworkers. Chronobiol Int, 2010 studied 856 men (518 dayworkers, 338 shiftworkers) and found that rotating shiftworkers who were homozygous for the serotonin transporter short allele (SLC6A4 S/S) and carried the CLOCK rs1554483G-rs4864548A haplotype had the highest values for diastolic blood pressure (P = 0.006), systolic blood pressure (P = 0.001), plasma triglycerides (P = 0.033), and number of metabolic syndrome components (P = 0.01). This study established that the metabolic risk conferred by this CLOCK haplotype is amplified when circadian rhythms are externally disrupted by rotating shift schedules.

Alzheimer's disease susceptibility. Chen et al. (2013)⁷⁷ Chen et al. (2013)
Chen Q et al. Functional CLOCK gene rs1554483 G/C polymorphism is associated with susceptibility to Alzheimer's disease in the Chinese population. J Int Med Res, 2013 found that the G allele was enriched among Alzheimer's patients (n = 130) compared to healthy controls (n = 188) in a Chinese cohort, specifically in individuals who did not carry the APOE ε4 allele. APOE ε4 itself is so strongly linked to AD risk that it may mask the CLOCK signal in carriers. This association is preliminary and requires replication in larger, ethnically diverse samples.

Population distribution of the risk haplotype. Flores et al. (2023)⁸⁸ Flores et al. (2023)
Flores SV et al. Prevalence of the GA risk haplotype of rs1554483 and rs4864548 polymorphisms of the CLOCK gene associated with obesity. Nutr Hosp, 2023 calculated haplotype frequencies across 26 world populations using 1000 Genomes data, finding that the rs1554483G-rs4864548A haplotype ranges from 17.9% in African populations to 57.4% in East Asian populations — a three-fold range that reflects strong continental stratification and may contribute to population differences in metabolic disease risk.

Practical Actions

The metabolic associations for the G allele are clearest in two high-risk contexts: shift work (where circadian disruption amplifies the genetic risk) and late eating patterns (where the circadian-metabolic axis is chronically misaligned). For G allele carriers, the evidence supports interventions that strengthen circadian alignment — principally consistent meal timing and protection of regular sleep-wake schedules.

For CG and GG carriers in occupations with rotating shifts, the Sookoian et al. 2010 data indicate that the combination of genetic predisposition and circadian disruption from shift work carries a meaningfully higher metabolic syndrome risk. Strategies that anchor the circadian clock — fixed anchor sleep times, bright light on starting shifts, and structured meal windows — are particularly relevant.

The NAFLD association suggests that liver-specific circadian metabolism may be altered by this haplotype. Avoiding prolonged fasting followed by large evening meals — a pattern that stresses hepatic lipid handling — is particularly relevant for G allele carriers concerned about liver health.

Interactions

The most important interaction documented for rs1554483 is with rs4864548, the second component of the obesity risk haplotype. Neither SNP alone showed as strong an effect as the paired haplotype in the Sookoian 2008 study, indicating haplotypic synergy⁹⁹ haplotypic synergy
Two variants that are more strongly associated with a phenotype together than either is individually, suggesting they tag the same functional effect or act in cis on the same allele. The risk haplotype (G at rs1554483 + A at rs4864548) should be considered together rather than evaluating either variant in isolation.

The interaction with SLC6A4 (serotonin transporter) variants in the context of shift work points to a broader gene-environment interaction where serotonin-circadian crosstalk amplifies metabolic risk. CLOCK and the serotonin transporter are both expressed in hypothalamic nuclei that regulate energy balance, and their combined dysregulation may compound appetite and metabolic disturbances.

rs1554483 should also be read alongside rs1801260 (CLOCK 3111T>C), which is mechanistically characterized as a miR-182 binding site variant affecting CLOCK mRNA stability and is the primary CLOCK variant linked to evening chronotype. The two variants are in different regions of the gene (rs1801260 in the 3'UTR; rs1554483 in an intron) and tag independent haplotype blocks, meaning they can independently contribute to CLOCK function — a carrier of both risk alleles would have two separate CLOCK-perturbing variants.

The FADS gene cluster on chromosome 11 encodes the two rate-limiting enzymes of long-chain PUFA synthesis¹¹ long-chain PUFA synthesis
polyunsaturated fatty acids (PUFAs) are essential fats. The short-chain forms (ALA, LA) come from plants; the long-chain forms (EPA, DHA, AA) are what the brain, heart, and immune system actually use. The FADS enzymes convert short-chain to long-chain forms. rs174561 is an intronic variant within FADS1 that tags a haplotype block governing delta-5 desaturase²² delta-5 desaturase
the enzyme encoded by FADS1 that catalyses a key step in converting fatty acid precursors: DGLA→AA in the omega-6 pathway and ETA→EPA in the omega-3 pathway activity. The C allele, which occurs in about 7% of Africans, 31% of Europeans, and over 50% of East Asians, is consistently associated with reduced enzymatic throughput — and carries an unexpected protective side effect: it independently lowers circulating LDL cholesterol through a separate microRNA pathway.

The Mechanism

rs174561 does not alter the FADS1 protein sequence (it sits in an intron), but it tags a haplotype block in strong linkage disequilibrium with regulatory variants that control FADS1 and FADS2 transcription. C allele carriers produce less delta-5 desaturase, slowing the final steps of long-chain PUFA synthesis in both the omega-6 and omega-3 pathways:

• Omega-6 arm: DGLA (dihomo-gamma-linolenic acid) accumulates; less converts to arachidonic acid (AA), the precursor to inflammatory prostaglandins.
• Omega-3 arm: ETA (eicosatetraenoic acid) is less efficiently converted to EPA; alpha-linolenic acid (ALA) from plant foods accumulates rather than flowing through to EPA and DHA.

A separate and distinct mechanism operates in parallel. rs174561 acts as a strong microRNA quantitative trait locus³³ microRNA quantitative trait locus
a variant that controls how much of a specific microRNA is produced in a tissue for miR-1908-5p: the C allele significantly increases miR-1908-5p abundance. This microRNA suppresses TGFB1 expression, which reduces BMP1 protein levels, which in turn decreases proteolytic cleavage of the LDL receptor — leaving more receptors intact on cell surfaces to clear LDL particles from the blood. The net effect: C allele carriers tend to have lower circulating LDL cholesterol, lower fasting glucose, and lower HbA1c — benefits that are mechanistically independent of the desaturase activity reduction.

The Evidence

Mathias et al. 2010⁴⁴ Mathias et al. 2010
Mathias RA et al. FADS genetic variants and omega-6 polyunsaturated fatty acid metabolism in a homogeneous island population. Journal of Lipid Research, 2010 studied 224 individuals from the Tangier island population and found rs174561 minor allele carriers consistently had lower omega-6 PUFAs including AA (p = 5.8×10⁻⁷ to 1.7×10⁻⁸) and substantially reduced FADS1 enzymatic activity (p = 2.11×10⁻¹³ to 1.8×10⁻²⁰). The exception was DGLA, which increased in minor allele carriers — consistent with substrate accumulation upstream of the blocked desaturation step.

Muzsik et al. 2018⁵⁵ Muzsik et al. 2018
Muzsik A et al. Associations between Fatty Acid Intake and Status, Desaturase Activities, and FADS Gene Polymorphism in Centrally Obese Postmenopausal Polish Women. Nutrients, 2018 measured red blood cell fatty acid composition in 128 women. Minor C allele carriers at rs174561 had 9.7% lower AA concentrations and 15–18% reduced delta-5 desaturase activity compared to TT homozygotes.

Al-Hilal et al. 2013⁶⁶ Al-Hilal et al. 2013
Al-Hilal M et al. Genetic variation at the FADS1-FADS2 gene locus influences delta-5 desaturase activity and LC-PUFA proportions after fish oil supplement. Journal of Lipid Research, 2013 examined 310 healthy subjects in the MARINA study and confirmed rs174561 minor allele association with reduced D5D activity (p = 4.5×10⁻¹⁸) and lower LC-PUFA proportions. Crucially, fish oil supplementation significantly increased D5D activity (p = 4.0×10⁻⁹) and improved PUFA profiles — demonstrating that preformed EPA/DHA supplementation can partly compensate for the reduced synthesis capacity.

Beehler et al. 2021⁷⁷ Beehler et al. 2021
Beehler K et al. A Common Polymorphism in the FADS1 Locus Links miR1908 to Low-Density Lipoprotein Cholesterol Through BMP1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021 established rs174561 as a strong miR-1908-5p QTL, with the C allele associating with higher miR-1908-5p, lower LDL-cholesterol, lower fasting glucose, and lower HbA1c. This LDL-lowering effect is independent of the PUFA conversion pathway.

Conway et al. 2021⁸⁸ Conway et al. 2021
Conway MC et al. Maternal and child fatty acid desaturase genotype as determinants of cord blood long-chain PUFA concentrations in the Seychelles Child Development Study. British Journal of Nutrition, 2021 demonstrated in 1,088 infants that rs174561 minor allele carrier mothers had lower cord blood AA:LA ratio and lower fetal LCPUFA concentrations — showing the impaired conversion is relevant even during fetal development.

Practical Actions

For C allele carriers (TC and CC), the impaired conversion of ALA to EPA means plant-based omega-3 sources (flaxseed, chia, walnuts) cannot reliably supply adequate EPA. Direct supplementation with preformed EPA and DHA from marine or algae sources bypasses the blocked desaturation step entirely. CC homozygotes show the strongest impairment and benefit most from higher doses (2–4 g EPA+DHA daily); TC heterozygotes typically need 1–2 g daily.

The miRNA-driven LDL benefit in C allele carriers is a passive biological effect requiring no additional action — but it does mean the net metabolic picture for C carriers is mixed: impaired PUFA synthesis coupled with modestly better LDL handling. Monitoring omega-3 index (RBC EPA+DHA%) is more useful than LDL alone for tracking whether supplementation is adequate.

For TT homozygotes (the most common genotype globally), desaturase activity is normal — but this higher enzymatic throughput also drives more AA production from dietary omega-6 precursors. Balancing the omega-6:omega-3 dietary ratio remains important to avoid excess AA-derived inflammatory signalling.

Interactions

rs174561 is in strong linkage disequilibrium (r² > 0.7) with rs174537, rs174547, rs174575, and rs3834458 within the FADS1 haplotype block. These variants co-segregate and amplify one another's effects on desaturase activity. Carriers who also have the low-activity alleles at multiple FADS1 cluster SNPs may have more pronounced impairment of PUFA synthesis than any single SNP predicts.

Dietary omega-6 intake modifies the impact of this variant: high linoleic acid intake (from seed oils) coupled with normal TT desaturase activity drives substantial AA production; in CC carriers, the same diet produces less AA but also less EPA — a different risk profile that specifically requires marine omega-3 compensation rather than omega-6 reduction.